Skip to main content

Month: May 2021

Valneva Announces an Indicative Price Range of its Previously Announced Proposed Global Offering

Saint-Herblain (France), May 5, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, in the context of its global offering to specified categories of investors comprised of (i) an initial public offering of American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a concurrent private placement of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement” and, together with the U.S. Offering, the “Global Offering”) announced on April 29, 2021, today announced that the offering price per ADSs in USD and the corresponding offering price per ordinary share is expected to range between...

Continue reading

Adevinta ASA (ADE) – Adevinta reports a solid start to the year, with strong financial performance in Q1

Total revenues1 up 6% at €200m EBITDA1 up 33% yoy to €57m Successful delivery of product roadmap Further progress ahead of the eBay Classifieds Group acquisitionOslo, 5 May 2021 – Adevinta ASA (ADE) (“Adevinta” or “the Company”) reported a solid start to 2021 with revenues1 up 6% compared to the same period last year, or up 7% excluding impacts of disposal, acquisitions and forex, demonstrating further performance improvement despite the challenging environment. Online classifieds revenues improved 8% (of which 5% is attributable to transactional services) compared to Q1 2020, when the Group saw strong performance until the Covid crisis started. Display advertising revenues increased 2% year-on-year. Disposals in Global Markets and the Grupo Zap acquisition had a 1-point positive impact on revenue growth, whilst changes in exchange...

Continue reading

Changes in Aktia’s Executive Committee and responsibilities

Aktia Bank PlcStock exchange release5 May 2021 at 8.05 a.m. Changes in Aktia’s Executive Committee and responsibilities Aktia informed on 30 April 2021 that it had completed the transaction regarding the acquisition of Taaleri’s wealth management operations. As a part of this change, the Group’s governance and organisational structure will be simplified. The aim with the changes is to make the responsibilities and leadership of the different business areas clearer.Sari Leppänen has been appointed EVP, Chief Information Officer (CIO) and member of the Executive Committee as of 9 August 2021. Leppänen is very experienced in leading the business and technology transformations in technology companies. She has previously worked as CIO and DPO for 3 Step IT. Anssi Huhta, EVP, Director for the business area Corporate Customers and member...

Continue reading

Three-month interim report (Q1) 2021

ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited) The first three months of 2021 represented ALK’s best-ever quarter, with revenue exceeding DKK 1 billion for the first time, despite the continuing effects of COVID. ALK saw revenue growth of 9% and tablet sales growth of 32%, driven by strong performances across the tablet portfolio in Europe and Japan. This comes on top of a strong first quarter last year that was largely unaffected by COVID. Operating profit (EBITDA) increased 14% despite increased activity levels across the organisation. ALK updates its financial outlook for 2021 on stronger tablet sales. Q1 2021 highlightsTotal revenue was up 9% in local currencies at DKK 1,021 million (956). Tablet sales grew by 32% to DKK 466 million (356) and continued to be the primary driver...

Continue reading

Uponor updates the savings target and schedule of its operational excellence programme

Uponor Corporation     Investor news      5 May 2021     07:50 EET  Uponor updates the savings target and schedule of its operational excellence programme Uponor communicated in its financial statements bulletin on 11 February that its operational excellence programme is progressing as planned and has yielded, as scheduled, its first results during 2020. “We are satisfied with the progress of the programme and expect that we will reach the original €20 million target of annual savings by the end of this year as planned. At the same time, we want to utilise the full savings potential identified during the planning and implementation of the programme and therefore extend the duration of the programme until the end of the first half of 2022 to generate €25 million annual savings in total,” comments Jyri Luomakoski, President and CEO, Uponor...

Continue reading

Clean Power Capital Provides Update on Its Investment in FusionOne‘s Waste to Electricity and Hydrogen Technology

VANCOUVER, British Columbia and IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”). The Company is pleased to provide an update on its investment in FusionOne Energy Corp. (“FusionOne”), a producer of technologies primarily for the conversion of plastic waste to hydrogen and clean electricity. FusionOne has instructed the fabrication facility to begin the production of its HydroPlas continuous cycle reactor, the center of its efficient Hydrogen producing system as well as the supporting proprietary technologies to be delivered in Q3 2021. FusionOne is striving to fit out its pre-commercialization site in Detroit, Michigan for its readiness to receive the first HydroPlas reactor. The FusionOne facility is situated in a...

Continue reading

MONMOUTH REAL ESTATE REPORTS RESULTS FOR THE SECOND QUARTER ENDED MARCH 31, 2021

HOLMDEL, NJ, May 04, 2021 (GLOBE NEWSWIRE) — Monmouth Real Estate Investment Corporation (NYSE:MNR) reported Net Income Attributable to Common Shareholders of $25.9 million or $0.26 per diluted share for the three months ended March 31, 2021 as compared to Net (Loss) Attributable to Common Shareholders of $(75.1) million or $(0.77) per diluted share for the three months ended March 31, 2020, representing an increase of $101.0 million or $1.03 per diluted share. During the three months ended March 31, 2021, we recognized a $19.2 million unrealized gain or $0.19 per diluted share as compared to an $(83.1) million unrealized (loss) or $(0.85) per diluted share for the three months ended March 31, 2020. Funds from Operations (FFO), which excludes unrealized and realized gains or losses from our securities portfolio, for the three months...

Continue reading

Maquia Capital Acquisition Corporation Announces Pricing of $160,000,000 Initial Public Offering

Miami, FL, May 04, 2021 (GLOBE NEWSWIRE) — Maquia Capital Acquisition Corporation (the “Company”) announced today that it priced its initial public offering of 16,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading tomorrow, Wednesday, May 5, 2021, under the ticker symbol “MAQCU”. Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade.  Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “MAQC,” and “MAQCW,” respectively. The...

Continue reading

Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product

Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field Calgary, Alberta, May 04, 2021 (GLOBE NEWSWIRE) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiXthin barium sulfate suspension. MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients. Voyageur has built a suite of barium radiographic contrast media products for global sales and distribution. The following products have been licensed: – SmoothX – For CT market – HDX – For Flouroscopy...

Continue reading

The Honest Company Announces Pricing of Initial Public Offering

LOS ANGELES, May 04, 2021 (GLOBE NEWSWIRE) — The Honest Company, Inc. (“The Honest Company”) today announced the pricing of its initial public offering of an aggregate of 25,807,000 shares of common stock at a price to the public of $16.00 per share. The Honest Company is offering 6,451,613 shares of common stock and the selling stockholders named in the prospectus are offering 19,355,387 shares of common stock. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,871,050 shares of common stock. The Honest Company will not receive any proceeds from the sale of shares by the selling stockholders. The shares are expected to begin trading on the Nasdaq Global Select Market on May 5, 2021 under the ticker symbol “HNST” and the offering is expected to close on May 7, 2021,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.